Exploring heterogeneity in randomized trials via meta-analysis

Drug Information Journal

Volumn 33, Issue 1, 1999, Pages 211-224

  Schmid, Christopher H ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

Bayesian models; Control rate; Expectation Maximization algorithm; Hierarchical models; Meta regression

Indexed keywords

ANISTREPLASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; STREPTOKINASE;

ACUTE HEART INFARCTION; ALGORITHM; ARTICLE; BAYES THEOREM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; EXPECTATION; FIBRINOLYTIC THERAPY; HUMAN; KIDNEY FAILURE; META ANALYSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; STATISTICAL ANALYSIS; TREATMENT PLANNING;

EID: 0033005849     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286159903300124     Document Type: Article

References (49)

1. Yusuf S. Meta-analysis of randomized trials: looking back and looking ahead. Control Clin Trials. 1997; 18:594-601.
2. Flather MD, Farkouh ME, Pogue JM, Yusuf S. Strengths and limitations of meta-analysis: larger studies may be more reliable. Control Clin Trials. 1997;18:568-579.
3. Anello C, Fliess JL. Exploratory or analytic meta-analysis: should we distinguish between them? J Clin Epidemiol. 1995;48:109-116.
4. Cappelleri JC, Ioannidis JPA, Schmid CH, de Ferranti SD, Aubert M, Chalmers TC, Lau J. Large trials vs meta-analysis of smaller trials: How do their results compare? JAMA. 1996;276:1332-1338.
5. ISIS-4 Collaborative Group. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet. 1995;345:669-685.
6. Woods KL, Fletcher S, Roffe C, Haider Y. Intravenous magnesium sulphate in suspected acute myocardial infarction: results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet. 1992;339:1553-1558.
7. Antman EM, Seelig MS, Fleishman K, Lau J, Kuntz K, Berkey CS, McIntosh MW. Magnesium in acute myocardial infarction: Scientific, statistical and economical reasons for its use. Cardiovascular Drugs Ther. 1996;10:297-301.
8. Lau J, Ioannidis JPA, Schmid CH. Summing up evidence: one answer is not always enough. Lancet. 1998;351:123-127.
9. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev. 1987;9: 1-30.
10. Smith GD, Song F, Sheldon RA. Cholesterol lowering and mortality: the importance of considering initial level of risk. Br Med J. 1993;306:1367-1373.
11. Thompson SG. Controversies in meta-analysis: the case of the trials of serum cholesterol reduction. Stat Methods Med Res. 1993;2:173-192.
12. Berlin JA, Antman EM. Advantages and limitations of metaanalytic regressions of clinical trials data. Online J Curr Clin Trials. 1994; June 4; 3:(Doc No 134).
13. Langbein LI, Lichtman AJ. Ecological inference. Newbury Park, CA; Sage Publications; 1978.
14. Morgenstern H. Uses of ecologic analysis in ecological research. Am J Public Health. 1982;72:1336-1344.
15. Gelman A, Carlin JB, Stern HS, Rubin DB. Bayesian Data Analysis. New York, NY: Chapman and Hall; 1995; chapter 5.
16. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
17. Honan MB, Harrell FE, Reimer KA, Califf RM, Mark DB, Pryor DB, Hlatky MA. Cardiac rupture, mortality and the timing of thrombolytic therapy. J Am College Cardiol. 1990;16:359-367.
18. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G, for the Modification of Diet in Renal Disease Study Group. The effects of dietary protein restriction and blood pressure control on the progression of renal disease. New Engl J Med. 1994;330:877-884.
19. Peterson J, Burkhart JM, Greene T, Hebert L, King A, Klahr S, Massry S, Siefter J, for the Modification of Diet in Renal Disease Study Group. Blood pressure control, proteinuria, and the progression of renal disease: The Modification of Diet in Renal Disease Study. Ann Int Med. 1995;123:754-762.
20. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, the Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. New Engl J Med. 1996;334:939-945.
21. Zucchelli P, Zuccala A, Borghi M, Fusaroli M, Sasdelli M, Stallone C. Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int. 1992;42:452-458.
22. Zucchelli P, Zuccala A, Gaggi R. Comparison of the effects of ACE inhibitors and calcium channel blockers on the progression of renal failure. Nephrology, Dialysis Transplant. 1995;10:46-51.
23. Kamper AL, Strandgarrd S, Leyssac PP. Effect of enalapril on the progression of chronic renal failure. Am J Hypertension. 1992;5:423-430.
24. Hannedouche T, Landais P, Goldfarb B, Esper E, Fournier A, Godin M. Randomized controlled clinical trial of enalapril and β-blockers in non-diabetic chronic renal failure. Br Med J. 1994;309:833-837.
25. Bannister KM, Weaver A, Clarkson AR, Woodroffe AJ. Effect of angiotensin-converting enzyme and calcium channel inhibition on progression of IgA nephropathy. In: Contributions to Nephrology, IgA Nephropathy: Pathogenesis and Treatment. Clarkson AR, Woodroffe AJ, eds. Basel: Karger; 1995; 184-193.
26. Becker GJ, Whilworth, JA, Ihle BU, Shahinfar S, Kincaid-Smith PS. Prevention of progression in non-diabetic chronic renal failure. Kidney Int. 1994; 45 (Suppl.1):167-170.
27. Ihle BU, Whitworth JA, Shahinfar S, Cnaan A, Kincaid-Smith PS. Angiotensin-converting-enzyme inhibition in non-diabetic progressive renal insufficiency: a controlled double-blind trial. Am J Kidney Disease. 1996;27:489-495.
28. Himmelmann A, Hansson L, Hansson BG, Hedstrand H, Skogstrom K, Ohrvik J. ACE inhibition preserves renal function better than beta-blockade in the treatment of essential hypertension. Blood Pressure. 1995;4:85-90.
29. Bianchi S, Bigazzi R, Baldari G, Campese VM. Long-term effects of enalapril and nicardipine on urinary albumin excretion in patients with chronic renal insufficiency: A 1-year follow-up. Am J Nephrol 1991;11:131-137.
30. Gruppo Italiano Studi Epidemiologici in Nefrologia (GISEN). Randomised placebo-controlled trial of effect of ramipril on declone in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997;349:1857-1863.
31. Okamura M, Kanayama Y, Negoro N, Inoue T, Takeda T. Long-term effects of calcium antagonists and angiotensin-converting-enzyme inhibitors in patients with chronic renal failure of IgA nephropathy. In Contributions to Nephrology, Calcium-regulating hormones. I. Role in Disease and Aging. Morii H, ed. Basel: Karger; 1991:161-165.
32. Apperloo AJ, Sluiter WJ, de Zeeuw D, de Jong PE. Is ACE inhibition superior to conventional antihypertensive therapy in retarding progression in non-diabetic renal disease? 1996 American Society of Nephrology 29th Annual Meeting. J Am Soc Nephrol.
33. Levey AS. Nephrology Forum: Measurement of renal function in chronic renal disease. Kidney Int. 1990;38:167-184.
34. Modification of Diet in Renal Disease Study Group. Effects of diet and antihypertensive therapy on creatinine clearance and serum creatinine concentration in the Modification of Diet in Renal Disease Study. J Am Soc Nephrol. 1996;7:556-565.
35. Modification of Diet in Renal Disease Study Group. Short-term effects of protein intake, blood pressure, and antihypertensive therapy on glomerular filtration rate in The Modification of Diet in Renal Disease Study. J Am Soc Nephrol. 1996;7:2097-2109.
36. Giatras I, Lau J, Levey AS. Effect of angiotensin-converting-enzyme inhibitors on the progression of nondiabetic renal disease: A meta-analysis of randomized trials. Ann Int Med. 1997;127:337-345.
37. Stewart LA, Clarke MJ. Practical methodology of meta-analyses (overviews) using updated individual patient data. Stat Med. 1995;14:2057-2079.
38. Selker HP, Griffith JL, Beshansky JR, Schmid CH, Califf RM, D'Agostino RB, Laks MM, Lee KL, Maynard C, Selvester RH, Wagner GS, Weaver WD. Patient-specific predictions of outcomes of thrombolytic therapy for real-time emergency clinical use: the Thrombolytic Predictive Instrument. Ann Int Med. 1997;127:538-556.
39. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet. 1994;343:311-322.
40. Brand R, Kragt H. Importance of trends in the interpretation of an overall odds ratio in the meta-analysis of clincial trials. Stat Med. 1992;11:2077-2082.
41. Senn S. Importance of trends in the interpretation of an overall odds ratio in the meta-analysis of clinical trials. Stat Med. 1994;13:293-296.
42. Sharp SJ, Thompson SG, Altman DG. The relation between treatment benefit and underlying risk in meta-analysis. Br Med J. 1996;313:735-738.
43. Yusuf S, Collins R, Peto R, et al. Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. European Heart J. 1985;6:556-585.
44. McIntosh M. The population risk as an explanatory variable in research synthesis of clinical trials. Stat Med. 1996;15:1713-1728.
45. Dempster AP, Laird NM, Rubin DB. Maximum likelihood from incomplete data via the EM algorithm (with discussion). J Roy Stat Society Series B. 1977; 39:1-38.
46. Tanner MA. Tools for Statistical Inference: Methods for the Exploration of Posterior Distributions and Likelihood Functions. Third ed. New York, NY: Springer-Verlag; 1996.
47. Gilks WR, Richardson S, Spiegelhalter DJ, eds. Markov Chain Monte Carlo in Practice. New York, NY: Chapman and Hall; 1996.
48. Schmid CH, Lau J, McIntosh MW, Cappelleri JC. An empirical study of the effect of the control rate as a predictor of treatment efficacy in meta-analysis of clinical trials. Stat Med. 1998;17:1923-1942.
49. Enkin MW, Keirse MJNC, Renfrew MJ, Neilson JP, eds. Pregnancy and Chilbirth Module: Cochrane Database of Systematic Reviews (Cochrane Updates on Disk). Disk Issue 2, Update Software. Oxford, England; 1994.